Phosphorylation of Yeast Pah1 Phosphatidate Phosphatase by Casein Kinase II Regulates Its Function in Lipid Metabolism*

Lu-Sheng Hsieh, Wen-Min Su, Gil-Soo Han, and George M. Carman1
From the Department of Food Science and the Rutgers Center for Lipid Research, New Jersey Institute for Food, Nutrition, and Health, Rutgers University, New Brunswick, New Jersey 08901

Pah1 phosphatidate phosphatase in Saccharomyces cerevisiae catalyzes the penultimate step in the synthesis of triacylglycerol (i.e. the production of diacylglycerol by dephosphorylation of phosphatidate). The enzyme playing a major role in lipid metabolism is subject to phosphorylation (e.g. by Pho85-Pho80, Cdc28-cyclin B, and protein kinases A and C) and dephosphorylation (e.g. by Nem1-Spo7) that regulate its cellular location, catalytic activity, and stability/degradation. In this work, we show that Pah1 is a substrate for casein kinase II (CKII); its phosphorylation was time- and dose-dependent and was dependent on the concentrations of Pah1 (Km = 0.23 μM) and ATP (Km = 5.5 μM). By mass spectrometry, truncation analysis, site-directed mutagenesis, phosphopeptide mapping, and phosphoamino acid analysis, we identified that >90% of its phosphorylation occurs on Thr-170, Ser-250, Ser-313, Ser-705, Ser-814, and Ser-818. The CKII-phosphorylated Pah1 was a substrate for the Nem1-Spo7 protein phosphatase and was degraded by the 20S proteasome. The prephosphorylation of Pah1 by protein kinase A or protein kinase C reduced its subsequent phosphorylation by CKII. The prephosphorylation of Pah1 by protein kinase A or protein kinase C reduced its subsequent phosphorylation by CKII. The prephosphorylation by protein kinase C reduced its subsequent dephosphorylation by protein kinase A but not by protein kinase C. The expression of Pah1 with combined mutations of S705D and 7A, which mimic its phosphorylation by CKII and lack of phosphorylation by Pho85-Pho80, caused an increase in triacylglycerol content and lipid droplet number in cells expressing the Nem1-Spo7 phosphatase complex.

The PAP2 enzyme (EC 3.1.3.4) catalyzes the Mg2+-dependent dephosphorylation of PA to produce DAG (1) (Fig. 1A). Because PAP controls the cellular levels of its substrate PA, which is used for the synthesis of essential membrane phospholipids (e.g. phosphatidylinositol) via CDP-DAG, and its product DAG, which is used for the synthesis of TAG and the membrane phospholipids phosphatidylcholine and phosphatidylethanolamine, the enzyme is widely recognized for its key regulatory role in lipid metabolism (2–8). Although it was identified in 1957 (1), it was not purified to near homogeneity until 1989 (9), and it took another 17 years before the PAH1 gene encoding the enzyme was identified in yeast3 (10). This discovery led to the revelation that mammalian lipin proteins, whose molecular function had not been known (11), were in fact PAP enzymes (10, 12). The analyses of yeast and mammalian cells that lack PAP have shown that this enzyme is a major regulator of lipid homeostasis and cell physiology (2, 3, 6, 8, 13, 14). For example, in yeast, PAP activity regulates phospholipid synthesis and nuclear/ER membrane growth (10, 15–18), the synthesis of TAG, the formation of lipid droplets (10, 17–19), vacuole homeostasis (20), and cell wall integrity (21, 22).

Inspired by the intrinsic, mode of action, and biochemical regulation of PAP has been gained through studies on the yeast enzyme (Fig. 1A) (2, 3, 13, 23, 24). The expression of PAH1 is regulated at the transcriptional level by growth phase and nutrient status (18, 25). The transcription of PAH1 is induced throughout growth, and its induction in the stationary phase is enhanced by inositol supplementation (18). This transcriptional regulation is mediated through the Ino2/Ino4/Opi1 regulatory circuit and by the transcription factors Gis1 and Rph1 (18). The PAH1 expression is also induced by zinc deficiency in the exponential phase through the Zap1-mediated transcriptional activation, resulting in an increase in synthesis of phosphatidylcholine via the CDP-choline branch of the Kennedy pathway (25). In contrast, the induction of PAH1 expression in zinc-replete stationary phase cells is responsible for increased synthesis and the accumulation of TAG that occurs at the expense of phospholipid synthesis (18). In response to growth phase and nutrient status, transcription factors that induce the PAH1 expression have negative regulatory effects on phospholipid synthesis genes (26, 27), and the opposing regulations collectively contribute to the balanced synthesis of membrane phospholipids and TAG.

The activity of Pah1 is governed by a conserved DXDX(T/V) catalytic motif within its haloacid dehalogenase-like domain and by a conserved glycine residue within its NLIP domain (10, 11, 16, 28, 29) (Fig. 1B). The enzyme is stimulated by negatively charged phospholipids (e.g. CDP-DAG and phosphatidylinositol) that increase its affinity for PA (30), but it is inhibited by positively charged sphingoid bases (e.g. sphinganine and phyt-

* This work was supported, in whole or in part, by National Institutes of Health Grant GM050679 from the United States Public Health Service. The authors declare that they have no conflicts of interest with the contents of this article.
1 To whom correspondence should be addressed: Dept. of Food Science, Rutgers University, 65 Dudley Rd., New Brunswick, NJ 08901. Tel.: 848-932-5407; E-mail: carman@aesop.rutgers.edu.
2 The abbreviations used are: PAP, phosphatidate phosphatase; PA, phosphatidate; TAG, triacylglycerol; DAG, diacylglycerol; CKII, casein kinase II; ER, endoplasmic reticulum; SC, synthetic complete.

3 In this paper, the term yeast is used interchangeably with Saccharomyces cerevisiae.
Phosphorylation of Pah1 Phosphatidate Phosphatase by CKII

In a previous study (40), we have shown that Pah1 is phosphorylated by CKII, a highly conserved serine/threonine protein kinase that is essential for cell viability in yeast (52–55). Pah1 is a phosphoprotein in the cytosol, and its phosphorylation is carried out by multiple protein kinases. Pah1 has been shown by phosphoproteomic studies to be phosphorylated on more than 30 serine/threonine sites (33, 46–51) and is a target for various protein kinases in vitro (40, 49). Our laboratory has taken a systematic approach to identify protein kinases that phosphorylate Pah1, to determine its phosphorylation sites, and to reveal the physiological relevance of its phosphorylation. We have shown that Pah1 is a bona fide substrate for Pho85-Pho80 (37), Cdc28-cyclin B (35), protein kinase A (38), and protein kinase C (42) by determining its phosphorylation sites (Fig. 1B). Some of the phosphorylation sites regulate the localization of Pah1, its PAP activity, or susceptibility to the 20S proteasomal degradation (35, 37, 38, 42). Moreover, the phosphorylation of Pah1 on some sites influences its phosphorylation on other sites by the same protein kinase or different protein kinases, indicating that it is subject to hierarchical phosphorylation (38, 42).

In a previous study (40), we have shown that Pah1 is phosphorylated by CKII, a highly conserved serine/threonine protein kinase that is essential for cell viability in yeast (52–55). The protein kinase is composed of two catalytic (i.e. Cka1 and Cka2) and two regulatory (i.e. Ckb1 and Ckb2) subunits (55–59). CKII generally phosphorylates proteins with the motif (S/T)/XX(E/D) but will also phosphorylate proteins with (S/T)X(E/D) or (S/T)(E/D) (56–58, 60). In this work, we have characterized the CKII-mediated phosphorylation of Pah1 and identified its phosphorylation sites (Fig. 1B). We also examined the CKII phosphorylation of Pah1 in relation to its phosphorylation by other protein kinases, the dephosphorylation of the CKII-phosphorylated Pah1 by the Nem1-Spo7 phosphatase, and the physiological consequences of cells expressing Pah1 with its CKII site mutations. The mutational analysis of Pah1 indicated that it regulates the synthesis of TAG and the number of lipid droplets through its cross-talk phosphorylation by the protein kinases CKII and Pho85-Pho80 as well as through its dephosphorylation by Nem1-Spo7 phosphatase.

Experimental Procedures

Reagents—Avanti Polar Lipids was the source of all lipids. Bradford (61) protein reagent, DNA size ladders, molecular mass protein standards, and reagents for electrophoresis and immunoblotting were obtained from Bio-Rad. Clontech was the supplier of carrier DNA for yeast transformation. Difco was the supplier of growth media. EMD Millipore was the source of cellulose and silica gel 60 TLC plates. GE Healthcare was the source of Igg-Sepharose, Q-Sepharose, PVDF membrane, and the enhanced chemiluminescence Western blotting detection kit. The yeast deletion consortium strains were from Invitrogen. National Diagnostics and PerkinElmer Life Sciences were the sources of scintillation counting supplies and radiochemicals, respectively. New England Biolabs was the source of enzyme reagents for DNA manipulations, human casein kinase II, and cyclin-dependent kinase-cyclin B. Promega was the source of bovine heart protein kinase A catalytic subunit and rat brain conventional protein kinase C. Qiagen was the source of nickel-nitrilotriacetic acid-agarose resin and the DNA gel extraction and plasmid DNA purification kits. Sigma-Aldrich was the source of ATP, PCR primers, 1,1-tosylamido-2-phenylethyl chloromethyl ketone-trypsin, protease and phosphatase inhibitors, phosphoamino acid standards, Triton X-100, Pronase S stain, bovine serum albumin, and rabbit anti-Protein A antibodies (product P3775, lot 053M4806V). Stratagene was the supplier of the QuikChange site-directed mutagenesis kit. Thermo Scientific was the source of mouse anti-phosphoglycerate kinase antibodies (product 459250, lot 459250/E1161), alkaline phosphatase-conjugated goat anti-rabbit IgG antibodies (product 31340, lot NJ178812), alkaline phospha-
Phosphorylation of Pah1 Phosphatidate Phosphatase by CKII

TABLE 1

| Strain | Relevant characteristics | Source/Reference |
|--------|--------------------------|------------------|
| E. coli DH5α | F⁻ d808dlacZAM15Δ (lacZYA-argF)U169 deor recA1 endA1 hisdRI7 (r6− m5−) proA.supE44 λ− thi-1 gyrA96 relA1 | Ref. 64 |
| BL21(DE3)pLysS | Fomp T07 hsdS2 (r6− m5−) gal dcm (DE3) pLysS | Novagen |

S. cerevisiae

BY4741-CKA2-TAP | TAP-tagged Cka2 expressed in strain BY4741 | Thermo Scientific |
| BY4741-ckaΔ | ckaΔ::kanMX4 derivative of BY4741 | Deletion consortium |
| BY4741-ckaΔ | ckaΔ::kanMX4 derivative of BY4741 | Deletion consortium |
| BY4741-ckbΔ | ckbΔ::kanMX4 derivative of BY4741 | Deletion consortium |
| SS1106 | pah1Δ::TRP1 derivative of RS453 | Ref. 15 |
| SS1132 | pah1Δ::TRP1 nem1Δ::HIS3 derivative of RS453 | Ref. 35 |
| W303-1A | MATA ade2-1 can1-100 his3-11,15 leu2-3,112 trpl-1 ura3-1 | Ref. 107 |
| GHY66 | pah1Δ::URA3 app1Δ::nasMX4::appp1Δ::TRP1/Kan' lpp1Δ::His3/Kan' derivative of W303-1A | Ref. 90 |

Strains and Growth Conditions—The strains used in this study are listed in Table 1. Escherichia coli strains DH5α and BL21(DE3)pLysS were used for the propagation of plasmids and for the expression of His6-tagged proteins, respectively. The bacterial cells were grown at 37 °C in LB medium (1% tryptone, 0.5% yeast extract, 1% NaCl, pH 7.0). The growth medium was supplemented with ampicillin (100 µg/ml) and chloramphenicol (34 µg/ml) to select for cells carrying plasmids for the expression of proteins (62). The expression of proteins in E. coli cells bearing derivatives of plasmid pET-15b was induced with 1 mM isopropyl β-D-1-thiogalactopyranoside. S. cerevisiae cells expressing TAP-tagged proteins were grown at 30 °C in YEPD medium (1% yeast extract, 2% peptone, and 2% glucose) (63). S. cerevisiae mutants cka1Δ, cka2Δ, ckb1Δ, and ckb2Δ were used to assess the effect of CKII-mediated phosphorylation on the abundance of Pah1, whereas the mutants pah1Δ and pah1Δ nem1Δ were used to assess the physiological impact of phosphorylation-deficient/mimicking Pah1. The pah1Δ app1Δ appp1Δ lpp1Δ mutant was used to assess the PAP activity of phosphorylation-deficient/mimicking Pah1 in response to temperature. The yeast were grown at 30 °C in standard synthetic complete (SC) medium containing 2% glucose (63). Appropriate amino acids were omitted from SC growth medium to select for cells carrying specific plasmids (63). Spectrophotometry (A₅₅₀) was used to estimate cell numbers in liquid cultures. Liquid growth medium was supplemented with agar (2% for yeast and 1.5% for E. coli) to prepare solid growth medium.

Plasmids and DNA Manipulations—Tables 2 and 3 contain a list of plasmids used in this study. Plasmid pGH313 directs the isopropyl β-D-1-thiogalactopyranoside-induced expression of His6-tagged Pah1 in E. coli (10). Plasmid pGH315 directs low copy expression of Pah1 in S. cerevisiae (35). The isolation of genomic and plasmid DNA, PCR amplification, digestion, and ligation of DNA were performed by standard molecular techniques (64, 65). pGH313(1–700) was constructed by generating a nonsense mutation at the 701st codon of PAH1 in pGH313. The derivatives of pGH313 and pGH315 that contain serine/threonine-to-alanine/aspartate/glutamate mutations were constructed by QuikChange site-directed mutagenesis with appropriate templates and primers as described by Choi et al. (35). All mutations were confirmed by DNA sequencing. Plasmid transformations of E. coli (64) and S. cerevisiae (66) were performed as described previously.

Preparations of Enzymes and the 20S Proteasome—CKII (52, 59) was purified from S. cerevisiae cells expressing the TAP-tagged Cka2 by IgG-Sepharose affinity chromatography as described by O’Hara et al. (33). The purification of Protein A-tagged Cka2 was confirmed by immunoblot analysis using anti-Protein A antibodies. His₆-tagged tobacco etch virus protease was used to remove the Protein A tag from the purified fusion protein (45). E. coli-expressed His₆-tagged wild type and mutant forms of yeast Pah1 (10) and His₆₈-tagged Pho85-Pho80 protein kinase complex (67) were purified by affinity chromatography with nickel-nitrilotriacetic acid-agarose as described previously. The 20S proteasome was purified from yeast expressing TAP-tagged Pre1 by IgG-Sepharose affinity chromatography (68), followed by the removal of the Protein A tag with His₆₈-tagged tobacco etch virus protease (45). Protein content of the purified enzymes and 20S proteasome was estimated by the method of Bradford (61) using bovine serum albumin as a standard, and the purity of the protein preparations was assessed by SDS-PAGE (69).

Analysis of Phosphorylation Sites by Mass Spectrometry—The CKII-phosphorylated Pah1 was analyzed by mass spectrometry at the Rutgers Mass Spectrometry Center for Integrative Neuroscience Research. Phosphorylated Pah1 in SDS-polyacrylamide gel slices was subjected to trypsin digestion, and the resulting peptides were analyzed by matrix-assisted laser desorption ionization tandem time-of-flight mass spectrometry to identify phosphopeptide candidates (35). Based on the phosphopeptide ion inclusion list, quadrupole time-of-flight and Orbitrap liquid chromatography-mass spectrometry/mass spectrometry were performed to identify phosphorylation sites (35).

Analysis of Phosphoamino Acids and Phosphopeptides—Radioactively phosphorylated Pah1 was resolved by SDS-PAGE, transferred to the PVDF membrane, and hydrolyzed with 6 N HCl at 110 °C for phosphoamino acid analysis or proteolytically cleaved with l-1-tosylamido-2-phenylethyl chloromethyl ketone-trypsin (for phosphopeptide analysis)
The acid hydrolysates were mixed with standard phosphoamino acids and were separated by two-dimensional electrophoresis on cellulose TLC plates. The tryptic digests were separated on the cellulose plates first by electrophoresis and then by TLC (70–72). Radioactive phosphoamino acids and peptides were visualized by phosphorimaging analysis. Non-radioactive phosphoamino acid standards were visualized by ninhydrin staining.

Preparation of Cell Extracts and Subcellular Fractionation—All steps were performed at 4 °C. Cell extracts were prepared by disruption of cells with glass beads using a BioSpec Products Mini-BeadBeater-16 (73). The cell disruption buffer contained 50 mM Tris-HCl (pH 7.5), 0.3 M sucrose, 10 mM 2-mercaptoethanol, 0.5 mM phenylmethanesulfonyl fluoride, 1 mM benzamidine, 5 μg/ml aprotinin, 5 μg/ml leupeptin, 5 μg/ml pepstatin, and phosphatase inhibitor mixture I and II (10). The cytosolic fraction. The samples for immunoblotting were normalized to total protein loading as determined by the Coomassie Blue-based assay of Bradford (61). Immunoblotting with PVDF membrane was performed as described previously (74–76). Protein transfer from SDS-polyacrylamide gels to PVDF membranes was monitored by Ponceau S staining. Rabbit anti-Protein A, rabbit anti-Pah1 PAP (35), rabbit anti-Cho1 phosphatidylyserine synthase (77), and mouse anti-phosphoglycerate kinase antibodies were used at a final concentration of 2 μg/ml. Secondary antibodies (e.g. goat anti-rabbit IgG or anti-mouse IgG) conjugated with alkaline phosphatase were used at a dilution of 1:5,000. Immune complexes were detected using the enhanced chemifluorescence immunoblotting substrate. Fluorimaging was used to acquire fluorescence signals from immunoblots, and the intensities of the images were analyzed by ImageQuant software. A standard curve was used to ensure that the immunoblot signals were in the linear range of detection.

Enzyme Assays—Protein kinase activity was measured at 30 °C by following the incorporation of radiolabeled phosphate from [γ-32P]ATP into Pah1 (35, 37, 38, 40, 42, 78). The reaction mixture for PKA contained 25 mM Tris-HCl (pH 7.5), 0.3 mM sucrose, 10 mM 2-mercaptoethanol, 0.5 mM phenylmethanesulfonyl fluoride, 1 mM benzamidine, 5 μg/ml aprotinin, 5 μg/ml leupeptin, 5 μg/ml pepstatin, and phosphatase inhibitor mixture I and II (10). The cytosolic (supernatant) and total membrane (pellet) fractions were separated by centrifugation at 100,000 × g for 1 h (73). The membrane pellets were suspended in the cell disruption buffer to the same volume of the cytosolic fraction. The method of Bradford (61) was used to estimate protein concentration with bovine serum albumin as a standard.

Immunoblotting—Proteins were separated by SDS-PAGE (69) using 8% slab gels. The samples for immunoblotting were normalized to total protein loading as determined by the Coomassie Blue-based assay of Bradford (61). Immunoblotting with PVDF membrane was performed as described previously (74–76). Protein transfer from SDS-polyacrylamide gels to PVDF
Phosphorylation of Pah1 Phosphatidate Phosphatase by CKII

Table 3

Plasmids used for Pah1 expression in S. cerevisiae

| Plasmid | Relevant characteristics | Source/Reference |
|---------|--------------------------|------------------|
| pRS415  | Low copy E. coli/yeast shuttle vector with LEU2 | Ref. 108 |
| pGH315  | PAH1 inserted into pRS415 | Ref. 35 |
| pGH315(T170A) | PAH1 (T170A) derivative of pGH315 | This study |
| pGH315(T170E) | PAH1 (T170E) derivative of pGH315 | This study |
| pGH315(S250A) | PAH1 (S250A) derivative of pGH315 | This study |
| pGH315(S250D) | PAH1 (S250D) derivative of pGH315 | This study |
| pGH315(S313A) | PAH1 (S313A) derivative of pGH315 | This study |
| pGH315(S313D) | PAH1 (S313D) derivative of pGH315 | This study |
| pGH315(S705A) | PAH1 (S705A) derivative of pGH315 | This study |
| pGH315(S705D) | PAH1 (S705D) derivative of pGH315 | This study |
| pGH315(S814A) | PAH1 (S814A) derivative of pGH315 | This study |
| pGH315(S814D) | PAH1 (S814D) derivative of pGH315 | This study |
| pGH315(S818A) | PAH1 (S818A) derivative of pGH315 | This study |
| pGH315(S818D) | PAH1 (S818D) derivative of pGH315 | This study |
| pGH315(4A) (CKII phosphorylation sites) | PAH1 (T170A/S313A/S705A/S818A) derivative of pGH315 | This study |
| pGH315(6A) (CKII phosphorylation sites) | PAH1 (T170E/S313D/S705A/S818A) derivative of pGH315 | This study |
| pGH315(7A) (Pho85-Pho80 phosphorylation sites) | PAH1 (T170E/S313D/S705D/S818D) derivative of pGH315 | This study |
| pGH315(7D(E)) (Pho85-Pho80 phosphorylation sites) | PAH1 (T170E/S313D/S705D/S818D) derivative of pGH315 | This study |
| pGH315(7A) | PAH1 (S110A/S114A/S168A/S602A/S723A/S744A/S748A) derivative of pGH315 | Ref. 35 |
| pGH315(7D(E)) | PAH1 (S110D/S114D/S168D/S602D/T723E/S744D/S748D) derivative of pGH315 | This study |
| pGH315(7A(1)) (Pho85-Pho80 phosphorylation sites) | PAH1 (S110A/S114A/S168A/S602A/S723A/S744A/S748A) derivative of pGH315 | This study |
| pGH315(7A(2)) (Pho85-Pho80 phosphorylation sites) | PAH1 (S110A/S114A/S168A/S602A/S723A/S744A/S748A) derivative of pGH315 | This study |
| pGH315(7D(E)(1)) | PAH1 (S110D/S114D/S168D/S602D/T723E/S744D/S748D) derivative of pGH315 | This study |
| pGH315(7D(E)(2)) | PAH1 (S110D/S114D/S168D/S602D/T723E/S744D/S748D) derivative of pGH315 | This study |
| pGH315(7D(E)(3)) | PAH1 (S110D/S114D/S168D/S602D/T723E/S744D/S748D) derivative of pGH315 | This study |
| pGH315(7D(E)(4)) | PAH1 (S110D/S114D/S168D/S602D/T723E/S744D/S748D) derivative of pGH315 | This study |

Phosphorylated Pah1 was visualized by phosphorimaging, and the extent of phosphorylation was quantified by ImageQuant software. PAP activity was visualized by phosphorimaging, and the extent of phosphorylation was quantified by ImageQuant software. PAP activity was measured at 30 °C by following the release of water-soluble [32P]Pi. The enzyme reactions were terminated by the addition of 6.7 μl of 4X Laemmli sample buffer (69), resolved by SDS-PAGE, and transferred to PVDF membranes. Phosphorylated Pah1 was visualized by phosphorimaging, and the extent of phosphorylation was quantified by ImageQuant software. PAP activity was measured at 30 °C by following the release of water-soluble [32P]Pi. The enzyme reactions were terminated by the addition of 6.7 μl of 4X Laemmli sample buffer (69), resolved by SDS-PAGE, and transferred to PVDF membranes. Phosphorylated Pah1 was visualized by phosphorimaging, and the extent of phosphorylation was quantified by ImageQuant software. PAP activity was measured at 30 °C by following the release of water-soluble [32P]Pi. The reaction mixture contained 25 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 2 mM dithiothreitol, 20 μM [γ-32P]ATP (2,400 cpm/μmol), 50 μg/ml Pah1, and protein kinase complex in a total volume of 20 μl. The reaction mixture contained 25 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 2 mM dithiothreitol, 20 μM [γ-32P]ATP (2,400 cpm/μmol), 50 μg/ml Pah1, and protein kinase complex in a total volume of 20 μl. The enzyme reactions were terminated by the addition of 6.7 μl of 4X Laemmli sample buffer (69), resolved by SDS-PAGE, and transferred to PVDF membranes. Phosphorylated Pah1 was visualized by phosphorimaging, and the extent of phosphorylation was quantified by ImageQuant software. PAP activity was measured at 30 °C by following the release of water-soluble [32P]Pi.
Results

Phosphorylation of Pah1 by CKII—We previously showed that Pah1 is phosphorylated in vitro by human CKII (40). In this work, we examined its phosphorylation using a purified preparation of yeast CKII. The Pah1 expressed and purified from E. coli was used as a substrate free of the endogenous phosphorylations that occur in S. cerevisiae (33). The unphosphorylated Pah1 was incubated with yeast CKII in the presence of [γ-32P]ATP, and its phosphorylation was monitored by following the incorporation of the radioactive γ-phosphate. Phosphorylated Pah1 was resolved by SDS-PAGE and then detected by phosphorimaging (Fig. 2A). As described previously (40), Pah1 was also phosphorylated by human CKII (Fig. 2A). Phosphoamino acid analysis showed that Pah1 is phosphorylated at both serine and threonine residues by yeast or human CKII (Fig. 2B). Phosphopeptide mapping analysis showed the identical patterns of phosphopeptide separation, indicating that yeast and human CKII enzymes phosphorylate Pah1 on the same sites (Fig. 2C). To conserve on the yeast CKII enzyme that had to be purified, we used the commercially prepared human CKII enzyme in further extensive phosphopeptide mapping experiments to identify the sites of phosphorylation (see below).

That Pah1 is a bona fide substrate of yeast CKII was shown by the kinase activity that was dependent on the time of reaction and the amount of protein kinase (Fig. 3, A and B, respectively). In addition, yeast CKII followed saturation kinetics with respect to the concentrations of Pah1 and ATP (Fig. 3, C and D, respectively). The $K_m$ value for Pah1 is similar to that of the Pho85-Pho80 and Cdc28-cyclin B protein kinases and is 1.9- and 3.2-fold lower, respectively, when compared with those of PKA and PKC (Table 4). The $K_m$ value for ATP of the CKII enzyme was also within the range of other protein kinases that phosphorylate Pah1 (Table 4). At the point of maximum phosphorylation, CKII catalyzed the incorporation of 2 mol of phosphate/mol of Pah1, a stoichiometry higher than that shown for PKA, PKC, and Cdc28-cyclin B but lower than that for Pho85-Pho80 (Table 4).

Effects of the CKII Phosphorylation of Pah1 on PAP Activity, 20S Proteasomal Degradation, and Nem1-Spo7 Protein Phosphatase Activity—The effect of CKII phosphorylation on Pah1 PAP activity was examined as a function of the PA surface concentration. As described previously (10), the unphosphorylated Pah1 exhibited positive cooperative (Hill number = 2.5) kinetics with respect to the PA concentration ($K_m = 2$ mol %) (Fig. 4A). The CKII phosphorylation of Pah1 did not have a significant effect on the $K_m$ or cooperativity for PA but had a small (13%) inhibitory effect on the $V_{max}$ of the reaction (Fig. 4A).

Pah1 is subject to the proteasome-mediated degradation in the stationary phase of growth (44). The degradation, which occurs by the 20S proteasome via a ubiquitin-independent mechanism, is regulated by phosphorylation (45). For example, the phosphorylations of Pah1 by Pho85-Pho80 and PKA prevent it from degradation by the 20S proteasome, whereas its phosphorylation by PKC stimulates the proteasomal degradation (45). Accordingly, we questioned whether the CKII phosphorylation of Pah1 affects its 20S proteasomal degradation. The E. coli–expressed Pah1 was first phosphorylated by yeast CKII and then incubated with the purified 20S proteasome. As described previously (45), the unphosphorylated Pah1 was degraded by the 20S proteasome in a time-dependent manner. The CKII-phosphorylated Pah1 was also degraded almost at the same rate by the 20S proteasome (Fig. 4B), indicating that the phosphorylation of Pah1 by CKII has no significant effect on its proteasomal degradation.

The Nem1-Spo7 protein phosphatase complex (34) dephosphorylates Pah1 (15, 33, 43) to facilitate its interaction with the nuclear/ER membrane (36, 39, 41) and to stimulate its PAP activity that is attenuated through the phosphorylations by Pho85-Pho80 and PKA (37, 38, 43). Here, we examined whether the CKII-phosphorylated Pah1 is dephosphorylated by Nem1-Spo7. Indeed, the CKII-phosphorylated Pah1 was a substrate for Nem1-Spo7 (Fig. 5). It was equally as good as the PKA-phosphorylated substrate and was 3.7- and 1.8-fold better than the PKC-phosphorylated and Cdc28-cyclin B-phosphorylated substrates, respectively. However, the CKII-phosphorylated Pah1 was 3.8-fold worse than the substrate phosphorylated by Pho85-Pho80.

Prephosphorylation of Pah1 by PKA or PKC Reduces Subsequent Phosphorylation by CKII, and Prephosphorylation by CKII Reduces Subsequent Phosphorylation by PKA—The rationale for using unphosphorylated Pah1 as a substrate for CKII was to eliminate potential effects of prior phosphorylations by other protein kinases. In this series of experiments, we...
Phosphorylation of Pah1 Phosphatidate Phosphatase by CKII

examined whether the phosphorylation of Pah1 by PKA, PKC, Pho85-Pho80, or Cdc28-cyclin B affects its subsequent phosphorylation by CKII. Pah1 was individually phosphorylated by various protein kinases with unlabeled ATP and then phosphorylated by yeast CKII with [γ-32P]ATP. Compared with Pah1 that was not subjected to prephosphorylation, Pah1 phosphorylated by PKA or PKC showed a reduction in its phosphorylation by CKII (Fig. 6A). Coincidentally, three serine residues (i.e. Ser-677, Ser-773, and Ser-788) of Pah1 are common target sites for PKA and PKC (38, 42) (Fig. 7A). The phosphorylation-deficient alanine mutations of four CKII sites (i.e. T170A/S313A/S705A/S818A; see below) obviated the inhibitory effect of the prephosphorylation by CKII (Fig. 6B).

CKII Phosphorylates Pah1 on Thr-170, Ser-250, Ser-313, Ser-705, Ser-814, and Ser-818—The strategy used to identify the CKII phosphorylation sites included mass spectrometry, phosphopeptide mapping, and phosphoamino acid analyses of wild type and mutant forms of Pah1. In our study by mass spectrometry, the E. coli-expressed wild type Pah1 was shown to be phosphorylated by human CKII on Ser-250 and Ser-814. This analysis also identified a phosphopeptide that contained Ser-704, Ser-705, and Ser-711, but it was unclear which serine residue(s) was phosphorylated. The five serine residues were individually changed to an alanine residue, and the mutant enzymes were expressed and purified from E. coli; they were phosphorylated by CKII and then subjected to proteolytic digestion and phosphopeptide mapping. This analysis showed that Ser-705 was the target of phosphorylation; a phosphopeptide present in the map of wild type Pah1 was missing in the map of the S705A mutant (Fig. 7C). The mutagenesis of Ser-250 or Ser-814 did not cause the loss of any major phosphopeptide, indicating that the serine residues are not major sites of phosphorylation (Fig. 7C). The multiple phosphopeptides that were still present in the map of the S705A mutant indicated that additional approaches were needed to identify major CKII target sites in Pah1.

To narrow down the regions of the CKII-phosphorylated Pah1, a series of its truncations (Fig. 7A) were phosphorylated by the protein kinase and then subjected to phosphopeptide mapping analysis (Fig. 7B). Compared with wild type Pah1, Pah1(1–821) showed no loss of phosphopeptide. In contrast, Pah1(1–700) and Pah1(1–646) showed the loss of two identical phosphopeptides, indicating that at least two CKII phosphory-
Phosphorylation of Pah1 Phosphatidate Phosphatase by CKII

Accordingly, another phosphorylation site was expected to be located between residues 701 and 752, and additional phosphorylation sites were expected to be located between residues 235 and 646. As described above, Ser-705 was identified as a CKII phosphorylation site by mass spectrometry and phosphopeptide mapping.

Phosphoproteome analyses (82, 83) indicated that Ser-311, Ser-327, Ser-475, and Ser-511, which are contained within residues 235–646, are sites of phosphorylation, but the protein kinases involved are not known. Phosphopeptide mapping analysis of the alanine mutants for each of these serine residues indicated that they are not major target sites for CKII. The analyses of the Pah1 sequence by the NetPhosK (84) and KinasePhos (85) algorithms indicated that it contains 14 putative CKII target sites (i.e. Ser-250, Ser-254, Ser-311, Ser-313, Thr-315, Thr-319, Ser-320, Ser-327, Thr-364, Ser-397, Ser-511, Thr-517, Thr-553, and Ser-613) within the residues 235–646. The phosphopeptide mapping analysis of the alanine mutants for each of these serine residues showed that Ser-313 was responsible for two phosphopeptides generated from the CKII-phosphorylated Pah1 (Fig. 7C).

We next sought to identify the CKII phosphorylation sites in the residues 753–821. This region contains three residues (i.e. Ser-814, Thr-816, and Ser-818) that are within the consensus motif for CKII. Two of these sites (e.g. Ser-814 and Ser-818) were previously identified by mass spectrometry of purified Pah1 (33), whereas all three sites have been identified in various phosphoproteomic analyses (82, 83, 86, 87). As indicated above, the phosphopeptide map of the S814A mutant was indistinguishable from that of the wild type enzyme. Of the remaining two sites, only the S818A mutation caused the loss of a phosphopeptide in the map (Fig. 7C). The phosphopeptide map of the S250A/S705A/S814A triple mutant showed only the loss of the phosphopeptide ascribed to Ser-705 (Fig. 7C). The map of the S313A/S705A double mutant showed the loss of the phosphopeptides ascribed to Ser-313 and Ser-705, and the only major peptide remaining in this map was ascribed to Ser-818 (Fig. 7C).

Pah1 was shown to be phosphorylated by CKII on a threonine residue(s) (Figs. 2B and 7D). However, no noticeable difference was shown in the phosphopeptide maps of the wild type and the alanine mutants for the threonine residues (i.e. T170A, T176A, T176A, T315A, T319A, T364A, T517A, T553A, and T816A) that were previously identified by phosphoproteome studies (82, 83, 86) or are located within a consensus CKII site (84, 85). This may be due to the fact that the extent of threonine phosphorylation was much lower than that of serine phosphorylation (Figs. 2B and 7D). Accordingly, we looked for a mutation(s) that affected the phosphoamino acid profile of Pah1. The phosphoamino acid analysis of all of the individual threonine-to-alanine mutants showed that only Thr-170 was the target site of CKII (Fig. 7D).

We examined the effects of phosphorylation site mutations individually or in combination on the extent of Pah1 phosphorylation by CKII (Fig. 8). Ser-313, Ser-705, Ser-814, and Ser-818 are in the context of the optimum recognition motif for CKII (60). The alanine mutations of these sites, with the exception of S814A, affected the phosphopeptide map of Pah1 and caused a
Phosphorylation of Pah1 Phosphatidate Phosphatase by CKII

**FIGURE 7.** Phosphopeptide mapping and phosphoamino acid analyses of Pah1 mutants identify its CKII phosphorylation sites. A, the diagram shows full-length and truncated forms of Pah1 used for phosphorylation and phosphopeptide mapping analysis. The positions of the identified phosphorylation sites are indicated in full-length Pah1. B–D, wild type Pah1 and its truncation and phosphorylation site mutants were expressed and purified from *E. coli*. Samples (1 μg) of the indicated forms of Pah1 were phosphorylated by 10 units of human CKII with 50 μM (γ-32P)ATP (2,500 cpm/pmol) for 10 min. The phosphorylated samples were resolved by SDS-PAGE and transferred to a PVDF membrane. The 32P-labeled Pah1 from the PVDF membrane was subjected to phosphopeptide mapping (B and C) or phosphoamino acid (D) analyses as described in the legend to Fig. 2. The identity of the phosphorylation sites in the radioactive phosphopeptides or phosphothreonine of wild type Pah1 was determined from the phosphopeptide or phosphoamino acid maps of the phosphorylation site mutant enzymes. The positions of the phosphopeptides or phosphothreonine that were absent in the mutant enzymes (indicated by the dotted line circles) but were present in wild type Pah1 are indicated. The unlabeled arrow in the phosphopeptide maps of the truncations of 1–700 and 1–646 points to the unidentified phosphopeptide that is more heavily labeled when compared with that found in the other maps. This figure does not show the negative results of all phosphopeptide mapping and phosphoamino acid analysis experiments performed on the mutants (see Table 2) discussed. The data shown are representative of three independent experiments.

Significant decrease in the phosphorylation by 48, 28, and 25%, respectively. Although S814A did not affect the phosphopeptide map of Pah1, the mutation caused a 13% decrease in phosphorylation. The alanine mutations for Thr-170 and Ser-250, respectively. Although S814A did not affect the phosphopeptide map of Pah1 and caused only small decreases in the phosphorylation by 6 and 1%, respectively. The 4A (T170A/S313A/S705A/S818A) and 6A (T170A/S250A/S313A/S705A/S814A/S818A) mutations, which include the major and minor phosphorylation site mutations, caused a greater reduction of Pah1 phosphorylation by 91 and 93%, respectively, indicating that the mutational effects are additive. The low level of phosphorylation shown by the 6A mutant suggests that a minor site(s) whose identity is yet unknown is involved in the phosphorylation of Pah1. These results, along with those of the phosphopeptide mapping analyses, showed that the phosphorylation efficiency on each site was different. For example, Ser-313 was the most heavily phosphorylated residue, whereas Ser-250 was the least phosphorylated residue. The phosphopeptide mapping results also showed that a single site mutation (e.g. S313A) not only abolishes the target phosphorylation but also affects the extent of phosphorylation on other sites (e.g. Ser-705) (Fig. 7C). We also noted in the truncation analysis (e.g. 1–700 and 1–646) that a major phosphopeptide appeared to the right of the phosphopeptide ascribed to Ser-818 (Fig. 7B, unlabeled arrow). The identity of this phosphopeptide was not determined. The complex nature of these phosphorylations suggests that the phosphorylation of one site affects the phosphorylation of another site. Thus, the hierarchical phosphorylation (88) may provide an explanation as to why the stoichiometry of 2 mol of phosphate/mol of Pah1 is lower than that expected from six sites of phosphorylation.

Effects of CKII Phosphorylation Site Mutations on the Abundance, Location, and Physiological Function of Pah1—A series of serine/threonine-to-alanine and -aspartate/glutamate mutations (Table 3) were constructed for the CKII phosphorylation sites in order to examine the physiologival effects of phosphorylation-deficient/mimicking Pah1. The mutant alleles of *PAH1* were expressed in pah1Δ or pah1Δ nem1Δ cells from a low copy plasmid. The rationale for expressing the mutant Pah1 in the nem1Δ background was to assess the dependence of its function on Nem1-Spo7 protein phosphatase and to assess the phosphorylation site mutations in a genetic background that favors the phosphorylation of non-mutated sites in Pah1. Immunoblot analysis of cell extracts showed that none of the CKII phosphorylation site mutations, individually or in combination, affected the abundance of Pah1. In addition, its abundance was not affected by mutations (e.g. cka1Δ, cka2Δ, ckb1Δ, or ckb2Δ) in any of the CKII subunits.

The subcellular location of Pah1 was examined in cells expressing the mutant alleles of *PAH1* for Thr-170, Ser-313,
Ser-705, and Ser-818. Mutations for Ser-250 and Ser-814 were not included in this analysis because they did not have a major effect on the phosphorylation of Pah1. The S705A mutant, expressed in either pah1Δ or pah1Δ nem1Δ cells, showed a 2-fold increase in membrane association when compared with the wild type control (Fig. 9A). Because the alanine mutations of the seven sites (i.e. 7A mutations) phosphorylated by Pho85-Pho80 (Fig. 1B) cause an increase in the association of Pah1 with the membrane (35), we questioned what effect the S705A mutation has on this regulation. In pah1Δ or pah1Δ nem1Δ cells, the combination of the S705A and 7A mutations showed no significant increase in the membrane association of Pah1 when compared with S705A or 7A (Fig. 9A). Except for S705A, other serine/threonine-to-alanine (Fig. 9A) or serine/threonine-to-aspartate/glutamate (Fig. 9B) mutations for the CKII phosphorylation sites showed little effect on the subcellular localization of Pah1.

As described previously (10, 15, 89), cells lacking Pah1 (i.e. pah1Δ mutant) exhibited a temperature-sensitive phenotype (Fig. 10A) that reflects the important role of PAP activity in cell physiology (10). The temperature sensitivity of the pah1Δ mutant, which expresses the Nem1-Spo7 phosphatase complex, was complemented by the PAH1 alleles with alanine or aspartate/glutamate mutations, alone or in combination, for the CKII phosphorylation sites (Fig. 10A). As described previously (35), pah1Δ nem1Δ mutant cells, which lack both Pah1 and the Nem1-Spo7 phosphatase complex, are also temperature-sensitive for growth (Fig. 10B). That this phenotype was poorly complemented by wild type PAH1 (Fig. 10B) reflects the importance of the Nem1-Spo7 phosphatase in Pah1 function (15, 33, 35). Moreover, the alanine mutations, alone or in combination, of the CKII sites did not have a major suppressive effect over that shown for the wild type enzyme (Fig. 10B).

Pah1-7A, which is defective in phosphorylation by Pho85-Pho80, bypasses the requirement of the Nem1-Spo7 phosphatase complex and complements the temperature-sensitive phenotype of the pah1Δ nem1Δ mutant (35, 38) (Fig. 10B). The molecular basis for this complementation is that the phosphorylation-deficient 7A mutations allow Pah1 to directly interact with the membrane as a functional enzyme in the absence of Nem1-Spo7 phosphatase activity (33, 35, 36, 40). Because the CKII phosphorylation-deficient S705A mutation affected the relative amounts of Pah1 in the cytosol and membrane fractions (Fig. 9A), we examined the temperature-sensitive phenotype of the pah1Δ and pah1Δ nem1Δ mutants expressing Pah1 with serine-to-alanine/aspartate mutations in Ser-705 in combination with the 7A mutations. Strikingly, the S705D mutation eliminated the ability of the 7A mutations to complement the temperature sensitivity of the pah1Δ mutant, but only when the Nem1-Spo7 phosphatase complex was present (Fig. 10A, bottom). In contrast, the S705D mutation did not interfere with the ability of the 7A mutations to complement the temperature sensitivity when Nem1-Spo7 was absent (Fig. 10B, bottom). The
Phosphorylation of Pah1 Phosphatidate Phosphatase by CKII

FIGURE 10. Effects of CKII and Pho85-Pho80 phosphorylation site mutations on the complementation of the pah1Δ temperature-sensitive phenotype and on PAP activity and stability in response to temperature. The indicated wild type and phosphorylation site mutant forms of Pah1 were expressed in the pah1Δ (A) and pah1Δ nem1Δ (B) mutants. The transformants were grown to stationary phase in SC-Leu medium at 30 °C; serial dilutions (10-fold) of the cells were spotted onto SC-Leu agar plates and incubated at 30 or 37 °C for 3–4 days. The data are representative of three independent experiments. 4A, 4D(E), 6A, and 6D(E), CKII phosphorylation site mutations; 7A and 7D(E), Pho85-Pho80 phosphorylation site mutations. C and D, cell extracts were prepared from pah1Δ app1Δ dpp1Δ lpp1Δ mutant cells expressing the wild type Pah1 and S705D/7A mutant enzymes. C, PAP activity was measured at the indicated temperatures for 20 min in a temperature-controlled water bath. D, samples were first incubated for 20 min at the indicated temperatures. After incubation, the samples were cooled in an ice bath for 10 min to allow for enzyme renaturation, and PAP activity was then measured for 20 min at 30 °C. The data shown are means ± S.D. (error bars) from triplicate enzyme determinations.

effect of the S705A/7A mutations expressed in pah1Δ (Fig. 10A) or pah1Δ nem1Δ (Fig. 10B) cells was the same as that governed by the 7A mutations alone.

Because temperature sensitivity of the pah1Δ mutant (10, 15, 89) has been ascribed to the loss of Pah1 PAP activity (10, 16), we questioned whether the Pah1-S705D/7A mutant enzyme is temperature-sensitive at 37 °C. To address this question, the Pah1-S705D/7A mutant enzyme was expressed in the pah1Δ app1Δ dpp1Δ lpp1Δ quadruple mutant, and the PAP activity was measured at 30 and 40 °C. The quadruple mutant was used for this experiment to eliminate interference from the promiscuous lipid phosphate phosphatase activities imparted by the APP1 (90, 91), DPP1 (92), and LPP1 (93) gene products. The Pah1 PAP activity in wild type cells at 40 °C was greater than that at 30 °C, and the level of PAP activity at 40 °C was not affected by the S705D/7A mutations (Fig. 10C). Moreover, the temperature stability profile of the Pah1 S705D/7A mutant enzyme was indistinguishable from the wild type control (Fig. 10D).

Pah1 has its greatest effect on lipid synthesis in the stationary phase of growth, when the synthesis of TAG occurs at the expense of membrane phospholipids (10, 17, 18). Accordingly, we examined the effects of the CKII phosphorylation-deficient/mimicking mutations on TAG levels in stationary phase cells. As described previously (35), expression of wild type Pah1 in pah1Δ nem1Δ mutant cells that lack the Nem1-Spo7 phosphatase showed a reduction (~70%) in the amount of TAG, but the expression of the Pah1-7A mutant complemented this phenotype (Fig. 11). The TAG content of the pah1Δ nem1Δ mutant expressing the 7A mutant enzyme was 3.5-fold higher than that of cells expressing the wild type enzyme. Unlike the Pho85-Pho80 site 7A mutations, none of the alanine mutations for the CKII sites complemented the loss of the Nem1-Spo7 phosphatase complex (Fig. 11A). Also, the CKII phosphorylation-deficient 4A mutations or the phosphorylation mimicking S705D mutation did not affect the 7A-mediated complementation of this phenotype (Fig. 11). Unexpectedly, the S705D mutation in combination with the 7A mutations caused a significant increase (70%) in the TAG content of pah1Δ mutant cells (Fig. 11A), the same cells where the S705D/7A mutations caused a lethal phenotype at 37 °C (Fig. 10A).

Because the S705D/7A mutations caused a significant increase in TAG content for stationary phase cells, we questioned what effect the mutations have on cytoplasmic lipid droplets. As described previously (17, 19), wild type cells had ~10 lipid droplets/cell (Fig. 12A). However, about 10% of the cells expressing the Pah1-S705D/7A contained about twice as many lipid droplets when compared with the wild type control cells (Fig. 12A). The number of lipid droplets/cell was not affected by the S705D or 7A mutations alone. This phenotype was growth phase-dependent; the population of cells with an excess in lipid droplet number increased from 2% in exponen-
Phosphorylation of Pah1 Phosphatidate Phosphatase by CKII

**Discussion**

PAP plays a major role in regulating the balance between the synthesis of TAG and membrane phospholipids from the PA node in lipid metabolism (2–8). Efforts to understand how PAP is regulated are clearly warranted, given its important role in lipid metabolism as well as its impact on various aspects of cell physiology (2, 3, 6, 8, 13, 14). As one of the most highly regulated enzymes in yeast lipid metabolism, Pah1 PAP is controlled at physiologic (2, 3, 6, 8, 13, 14). As one of the most highly regulated

stationary phase (12-h growth) to 10% in stationary phase (60-h growth) (Fig. 12B).

**FIGURE 11.** TAG synthesis is affected by the CKII phosphorylation state of Pah1 at Ser-705 in combination with its 7A mutations for the Pho85-Pho80 phosphorylation sites. The indicated wild type and phosphorylation site alanine (A) or aspartate/glutamate (B) mutant forms of Pah1 were expressed in pah1Δ and pah1Δ nem1Δ cells. Cultures were grown to the stationary phase (A260 = 3) in the medium containing [2-14C]acetate (1 μCi/ml) to label lipids. The lipids were extracted and separated by one-dimensional TLC, and the phosphor images were subjected to ImageQuant analysis. The percentage shown for TAG was normalized to the total 14C-labeled chloroform-soluble fraction. Each data point represents the average of three experiments ± S.D. (error bars). The data points for the wild type control and 7A mutant expressed in either pah1Δ or pah1Δ nem1Δ in A and B are the same for the purpose of comparison. 4A and 7A, CKII and Pho85-Pho80 phosphorylation site mutations, respectively. *, p < 0.05 versus control.

Posttranslational regulation of Pah1 has been facilitated through analyses of its phosphorylation by Pho85-Pho80 (37), Cdc28-cyclin B (35), PKA (38), and PKC (42) as well as through analyses of its dephosphorylation by the Nem1-Spo7 protein phosphatase (43). In this work, we have established that Pah1 is a substrate for phosphorylation by CKII by identifying its six Ser/Thr residues as phosphorylation sites (Fig. 1B). By mutational analysis of the CKII sites, we discovered that the phosphorylation of Pah1 on Ser-705, in conjunction with its dephosphorylation on the Pho85-Pho80 sites, regulates its role in TAG synthesis.

The effects of the CKII phosphorylation of Pah1 differed from those of its phosphorylation by other protein kinases that phosphorylate the enzyme. The phosphorylations by Pho85-Pho80 (37) and PKA (38) have a relatively strong inhibitory effect on PAP activity, whereas the phosphorylation by CKII had only a weak inhibitory effect on activity. The phosphorylation by PKC (42) has a small stimulatory effect on PAP activity, whereas the phosphorylation by Cdc28-cyclin B (35) has no effect on activity. These protein kinases also have differential regulatory effects on Pah1 location and on its susceptibility to degradation by the 20S proteasome. The cytosolic location of Pah1 is largely controlled by the Pho85-Pho80 phosphorylations of its seven target sites (33, 35, 37), and this regulation is accentuated by the phosphorylation of the unique PKA site Ser-10 (38). Data indicate that these phosphorylations cause the retention of Pah1 in the cytosol (33, 35, 37, 38). As discussed herein, the 7A mutations of the Pho85-Pho80 phosphorylation sites bypass the Nem1-Spo7-mediated dephosphorylations that are required for Pah1 membrane association and the PAP function to synthesize TAG (33, 35–37). The three Cdc28-cyclin B phosphorylation sites, which overlap with three of the Pho85-Pho80 sites (Fig. 1B), have a relatively small effect on Pah1 location and its physiological function (35, 37), and the PKC phosphorylation has no effect on the location and function to synthesize TAG (42). The CKII site mutation S705A caused an increase in membrane association, but unlike the 7A mutations, the S705A mutation did not bypass the requirement for the Nem1-Spo7 phosphatase (e.g. did not complement the temperature-sensitive phenotype or defect in TAG content of the nem1Δ mutant). This observation substantiates the importance of dephosphorylating the seven Pho85-Pho80 sites that also have a major stimulatory effect on PAP activity (43). None of the other CKII phosphorylation site mutations affected the localization of Pah1; nor did they have an appreciable effect on the complementation of the temperature sensitive phenotype caused by the nem1Δ mutation. With respect to Pah1 degradation, the phosphorylations by Pho85-Pho80 and PKA have the major role in protecting Pah1 from the 20S proteasome (37, 38, 44, 45), whereas the phosphorylation by PKC favors degradation, but only when the enzyme is not phosphorylated by Pho85-Pho80 (42). In contrast, the CKII phosphorylation had no effect on the degradation by the 20S proteasome.

The Nem1-Spo7 phosphatase plays a crucial role in governing the phosphorylation state of Pah1, and this protein phosphatase had the highest activity on the sites that are phosphorylated by Pho85-Pho80 (43), which is consistent with the major effects imparted by the 7A mutations (33, 35, 37). The activity of
Phosphorylation of Pah1 Phosphatidate Phosphatase by CKII

The differential effects of the various protein kinases on Pah1 are further complicated by the hierarchical nature of the phosphorylations. For example, the prephosphorylation of Pah1 by Pho85-Pho80 inhibits its subsequent phosphorylation by PKC (42). As indicated above, this regulation impacts the susceptibility of Pah1 degradation by the 20S proteasome (42, 45); for proteasomal degradation, the Pho85-Pho80 sites are further complicated by the hierarchical nature of the phosphorylations. For example, the prephosphorylation of Pah1 by CKII reduces its subsequent phosphorylation by CKII and that its prephosphorylation by CKII reduces the subsequent phosphorylation by PKA. The CKII phosphorylation-mimicking S705D mutation abrogates the Pho85-Pho80 phosphorylation-deficient 7A mutant complementation of the pah1Δ temperature-sensitive phenotype, but only when Nem1-Spo7 phosphatase is present. The lack of growth at 37 °C was not attributed to the mutations causing a temperature-sensitive PAP activity, indicating that the S705D/7A mutant enzyme is functional in vivo at 37 °C. Moreover, the S705D/7A mutant enzyme supported cell growth at the restrictive temperature when the Nem1-Spo7 phosphatase complex was absent. At the permissive temperature for growth, the S705D/7A mutations caused a significant 70% in TAG content, but again, only when the Nem1-Spo7 phosphatase complex was present. Moreover, the Nem1-Spo7 phosphatase complex was required for the unique phenotypes caused by the S705D/7A mutations.
Phosphorylation of Pah1 Phosphatidate Phosphatase by CKII

Author Contributions—L.-S. H. and W.-M. S. performed the experiments and prepared the manuscript. G.-S. H. and G. M. C. directed the research and contributed to the preparation of the manuscript. All authors analyzed the results and approved the final version of the manuscript.

Acknowledgments—We acknowledge Symeon Siniossoglou for supplying the pah1Δ and pah1Δ nem1Δ mutants used in this study. The mass spectrometry data were obtained from an instrument purchased in part by National Institutes of Health Grant NS046593 for the support of the Rutgers Mass Spectrometry Center for Integrative Neuroscience Research.

References

1. Smith, S. W., Weiss, S. B., and Kennedy, E. P. (1957) The enzymatic dephosphorylation of phosphatidic acids. J. Biol. Chem. 228, 915–922
2. Pascual, F., and Carman, G. M. (2013) Phosphatidate phosphatase, a key regulator of lipid homeostasis. Biochim. Biophys. Acta 1831, 514–522
3. Carman, G. M., and Han, G.-S. (2009) Phosphatidic acid phosphatase, a key enzyme in the regulation of lipid synthesis. J. Biol. Chem. 284, 2593–2597
4. Brindle, D. N., Pilquíll, C., Sariahemtougal, M., and Keue, K. (2009) Phosphatidate degradation: phosphatidate phosphatases (lipins) and lipid phosphatase phosphatases. Biochim. Biophys. Acta 1791, 956–961
5. Brindle, D. N., and Waggner, D. W. (1996) Phosphatidyl phosphorylation and signal transduction. Chem. Phys. Lipids 80, 45–57
6. Reue, K., and Brindle, D. N. (2008) Multiple roles for lipins/phosphatidate phosphatase enzymes in lipid metabolism. J. Lipid Res. 49, 2493–2503
7. Reue, K. (2009) The lipin family: mutations and metabolism. Curr. Opin. Lipidol. 20, 163–170
8. Reue, K., and Dwyer, J. R. (2009) Lipin proteins and metabolic homeostasis. J. Lipid Res. 50, S109–S114
9. Lin, Y.-P., and Carman, G. M. (1989) Purification and characterization of the yeast lipin homolog PAH1. J. Biol. Chem. 264, 8641–8645
10. Han, G.-S., Wu, W.-L., and Carman, G. M. (2006) The Saccharomyces cerevisiae lipin homolog is a Mg2+-dependent phosphatidate phosphatase enzyme. J. Biol. Chem. 281, 9210–9218
11. Péterfy, M., Phan, J., Xu, P., and Reue, K. (2001) Lipidostrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin. Nat. Genet. 27, 121–124
12. Donkor, J., Sariahemtougal, M., Dewald, J., Brindle, D. N., and Reue, K. (2007) Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. J. Biol. Chem. 282, 3450–3457
13. Carman, G. M., and Han, G.-S. (2006) Roles of phosphatidate phosphatase enzymes in lipid metabolism. Trends Biochem. Sci. 31, 694–699
14. Csaki, L. S., Dwyer, J. R., Fong, L. G., Tontonoz, P., Young, S. G., and Reue, K. (2001) Lipidostrophy in the fld mutant used in this study. The
15. Santos-Rosa, H., Leung, J., Grimsey, N., Peak-Chew, S., and Siniossoglou, S. (2005) The yeast lipin Smplp couples phospholipid biosynthesis to nucleic acid growth. EMBO J. 24, 1931–1941
16. Han, G.-S., Siniossoglou, S., and Carman, G. M. (2007) The cellular functions of the yeast lipin homolog Pah1p are dependent on its phosphatidate phosphatase activity. J. Biol. Chem. 282, 37026–37035
17. Fakas, S., Qiu, Y., Dixon, J. L., Han, G.-S., Ruggles, K. V., Garbarino, J., Sturley, S. L., and Carman, G. M. (2011) Phosphatidate phosphatase activity plays a role in protection against fatty acid-induced toxicity in yeast. J. Biol. Chem. 286, 29074–29085
18. Pascual, F., Soto-Cardalda, A., and Carman, G. M. (2013) PAH1-encoded phosphatidate phosphatase plays a role in the growth phase- and inositol-mediated regulation of lipid synthesis in Saccharomyces cerevisiae. J. Biol. Chem. 288, 35781–35792
19. Adeyo, O., Horn, P. J., Lee, S., Binns, D. D., Chandrasah, A., Chapman, R. J., and Fong, L. G. (2007) Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. J. Biol. Chem. 282, 3450–3457
Phosphorylation of Pah1 Phosphatidate Phosphatase by CKII

K. D., and Goodman, J. M. (2011) The yeast lipid orthologue Pah1p is important for biogenesis of lipid droplets. J. Cell Biol. 192, 1043–1055

20. Sassier, T., Qiu, Q. S., Karunakaran, S., Padolina, M., Reyes, A., Flood, B., Smith, S., Gonzales, C., and Fratti, R. A. (2012) The yeast lipid 1 orthologue Pah1p regulates vacuole homeostasis and membrane fusion. J. Biol. Chem. 287, 2221–2236

21. Lussier, M., White, A. M., Sheraton, J., di Paolo, T., Treadwell, J., Southard, S. B., Horenstein, C. I., Chen-Weiner, J., Ram, A. F., Kapteyn, J. C., Roemer, T. W., Vo, D. H., Bondoc, D. C., Hall, J., Zhong, W. W., et al. (1997) Large scale identification of genes involved in cell surface biosynthesis and architecture in Saccharomyces cerevisiae. Genetics 147, 435–450

22. Ruiz, C., Cid, V. I., Lussier, M., Molina, M., and Nombela, C. (1999) A large-scale sonication assay for cell wall mutant analysis in yeast. Yeast 15, 1001–1008

23. Siniossoglou, S. (2009) Lipins, lipids and nuclear envelope structure. Traffic 10, 1181–1187

24. Siniossoglou, S. (2013) Phospholipid metabolism and nuclear function: roles of the lipin family of phosphatidic acid phosphatases. Biochem. Biophys. Acta 1831, 575–581

25. Soto-Cardalda, A., Fakas, S., Pascual, F., Choi, H. S., and Carman, G. M. (2012) Phosphatidate phosphatase plays role in zinc-mediated regulation of phospholipid synthesis in yeast. J. Biol. Chem. 287, 968–977

26. Carman, G. M., and Han, G.-S. (2011) Regulation of phospholipid synthesis in yeast Saccharomyces cerevisiae. Ann. Rev. Biochem. 80, 859–883

27. Henry, S. A., Kohwein, S. D., and Carman, G. M. (2012) Metabolism and regulation of glycerolipids in the yeast Saccharomyces cerevisiae. Genetics 190, 317–349

28. Koonin, E. V., and Tatusov, R. L. (1994) Computer analysis of bacterial haloacid dehalogenases defines a large superfamily of hydrolases with specific for the Pho85-Pho80 protein kinase phosphorylation sites. J. Biol. Chem. 289, 34699–34708

29. Koonin, E. V., and Tatusov, R. L. (1994) Regulation of phosphatidate phosphatase in yeast Saccharomyces cerevisiae. J. Biol. Chem. 269, 1486–1498

30. Koonin, E. V., and Tatusov, R. L. (1994) Computer analysis of bacterial haloacid dehalogenases defines a large superfamily of hydrolases with specific for the Pho85-Pho80 protein kinase phosphorylation sites. J. Biol. Chem. 289, 34699–34708

31. Wu, W.-I., Lin, Y.-P., Wang, E., Merrill, A. H., Jr., and Carman, G. M. (1994) Regulation of phosphatidate phosphatase by CKII. J. Biol. Chem. 269, 1486–1498

32. Wu, W.-I., and Carman, G. M. (1996) Regulation of phosphatidate phosphatase by CKII. J. Biol. Chem. 271, 33364–33376

33. Wu, W.-I., and Carman, G. M. (1994) Regulation of phospholipid and membrane biogenesis by the acidic tail of the phosphatidate phosphatase Pah1p. Mol. Biol. Cell 24, 2124–2133

34. Siniossoglou, S., Santos-Rosa, H., Rappsilber, J., Mann, M., and Hurt, E. (2007) A novel complex of membrane proteins required for formation of Pah1p encoded phosphatidate phosphatase interaction with liposome membranes. J. Lipid Res. 53, 522–528

35. Choi, H.-S., Su, W.-M., Morgan, J. M., Han, G.-S., Xu, Z., Karanasios, E., Rachidi, N., Lee, S. J., Mah, A. S., et al. (2013) Yeast Nem1-Spo7 protein kinase activity on Pah1p phosphatidate phosphatase is specific for the Pho85-Pho80 protein kinase phosphorylation sites. J. Biol. Chem. 289, 1190–1197

36. Ubersax, J. A., Woodbury, E. L., Quan, P. N., Paraz, M., Bleveth, J. D., Shah, K., Shokat, K. M., and Morgan, D. O. (2003) Targets of the cyclin-dependent kinase Cdk1. Nature 425, 859–864

37. Ptacek, J., Devgan, G., Michaud, G., Zhu, H., Zhu, X., Fasolo, J., Guo, H., Jona, G., Breitkreutz, A., Sopko, R., McCartney, R. R., Schmidt, M. C., Rachidi, N., Lee, S. J., Mah, A. S., et al. (2005) Global analysis of protein phosphorylation in yeast. Nature 438, 679–684

38. Dey, J., Devgan, G., Myllyla, L., Huang, W.-S., Booth, A., and O’Shea, E. K. (2005) Combining chemical genetics and proteomics to identify the protein kinase substrates. Proc. Natl. Acad. Sci. U.S.A. 102, 17940–17945

39. Mah, A. S., Elia, A. E., Devgan, G., Ptacek, J., Schutkowski, M., Snyder, R. E., and O’Shea, E. K. (2005) Targeting the kinase scaffold for regulation of phosphoprotein signaling in yeast. Proc. Natl. Acad. Sci. U.S.A. 102, 17940–17945

40. Mura, E., Rump, S., Myllyla, L., Huang, W.-S., Booth, A., and O’Shea, E. K. (2005) Combining chemical genetics and proteomics to identify the protein kinase substrates. Proc. Natl. Acad. Sci. U.S.A. 102, 17940–17945

41. Litchfield, D. W. (2003) Protein kinase CK2: structure, regulation and functions in Saccharomyces cerevisiae. J. Biol. Chem. 280, 2124–2133

42. Litchfield, D. W. (2003) Protein kinase CK2: structure, regulation and functions in Saccharomyces cerevisiae. J. Biol. Chem. 280, 2124–2133

43. Nakanishi, K., Baccus, C., and Glover, C. V. (1994) Cloning and characterization of yeast casein kinase II. Cell Biochem. Funct. 12, 391–408

44. Pedro, A., Poore, T., Bandhakavi, S., McCann, R. O., Hanna, D. E., and O’Shea, E. K. (2005) Integrating chemical genetics and proteomics to identify the protein kinase substrates. Proc. Natl. Acad. Sci. U.S.A. 102, 17940–17945

45. Reed, J. C., Bidwai, A. P., and Glover, C. V. C. (1994) Cloning and disruption of the CKA1 gene encoding the yeast casein kinase II. Mol. Cell Biol. 14, 4981–4990
Phosphorylation of Pah1 Phosphatidate Phosphatase by CKII

58. Bidwai, A. P., Reed, J. C., and Glover, C. V. (1995) Cloning and disruption of CKII, the gene encoding the 38-kDa β subunit of Saccharomyces cerevisiae. J. Biol. Chem. 270, 10395–10404

59. Padmanabha, R., and Glover, C. V. C. (1987) Site specificity of casein kinase-2 (TS) from rat liver cytosol. A study with model peptide substrates. Eur. J. Biochem. 160, 239–244

60. Marin, O., Meggio, F., Marchiori, F., Borin, G., and Pinna, L. A. (1986) Site specificity of casein kinase II of yeast contains two distinct α polypeptides and an unusually large β subunit. J. Biol. Chem. 262, 1829–1835

61. Carman, G. M., and Lin, Y.-P. (1991) Phosphatidate phosphatase from Saccharomyces cerevisiae. J. Biol. Chem. 269, 18192–18200

62. Han, G.-S., Sreenivas, A., Choi, M.-G., Chang, Y.-F., Martin, S. S., Baldwin, E. P., and Carman, G. M. (2005) Expression of human CTP synthetase in Saccharomyces cerevisiae reveals phosphorylation by protein kinase A. J. Biol. Chem. 280, 38328–38336

63. Rose, M. D., Winston, F., and Heiter, P. (1990) Methods in Yeast Genetics: A Laboratory Course Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY

64. Leggett, D. S., Glickman, M. H., and Finley, D. (2005) Purification of proteasomes, proteasome subcomplexes, and proteasome-associated proteins from budding yeast. Methods Mol. Biol. 301, 57–70

65. Innis, M. A., and Gelfand, D. H. (1990) in PCR Protocols: A Guide to Methods and Applications (Innis, M. A., Gelfand, D. H., Sninsky, J. J., and White, T. J., eds) pp. 3–12, Academic Press, Inc., San Diego

66. Ito, H., Fukuda, Y., Murata, K., and Kimura, A. (1983) Transformation of intact yeast cells treated with alkali cations. J. Bacteriol. 153, 163–168

67. Bartfay, D. A., Springer, M., King, D. S., and O’Shea, E. K. (2001) Multi-site phosphorylation of Pho4 by the cdc1-cdc2 Pho80-Pho85 is semi-proressive with site preference. J. Mol. Biol. 316, 997–1010

68. Irie, K., Takase, M., Araki, H., and Oshima, Y. (1993) A gene, SMP2, encodes a 38-kDa protein A. J. Biol. Chem. 268, 680–685

69. Boyle, W. J., van der Geer, P., and Hunter, T. (1991) Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates. Methods Enzymol. 201, 110–149

70. Yeast. Methods Enzymol. 197, 548–553

71. Guengerich, F. P., Wang, P., and Davidson, N. K. (1982) Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry 21, 1698–1706

72. Burnette, W. (1981) Western blotting: electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radiolabeled protein A. Anal. Biochem. 112, 195–203

73. Haid, A., and Suisa, M. (1983) Immunoochemical identification of membrane proteins after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Methods Enzymol. 96, 192–205

74. Choi, H.-S., Han, G.-S., and Carman, G. M. (2010) Phosphorylation of yeast phosphatidylserine synthase by protein kinase A: identification of Ser46 and Ser47 as major sites of phosphorylation. J. Biol. Chem. 285, 11526–11536

75. Chang, Y.-F., and Carman, G. M. (2006) Casein kinase II phosphorylation of the yeast phospholipid synthesis transcription factor Opi1p. J. Biol. Chem. 281, 4754–4761

76. Morlock, K. R., Lin, Y.-P., and Carman, G. M. (1988) Regulation of phosphatidate phosphatase activity by inositol in Saccharomyces cerevisiae. J. Bacteriol. 170, 3561–3566

77. Bligh, E. G., and Dyer, W. J. (1959) A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911–917

78. Kedersha, N. L., Millar, W., and Hunter, T. (1995) Phosphorylation of CTP synthetase by casein kinase II. J. Biol. Chem. 270, 14983–14988

79. Toke, D. A., Bennett, W. L., Ostrander, D. B., Oshiro, I., Cremesti, A., Voelker, D. R., Fischli, A. S., and Carman, G. M. (1998) Isolation and characterization of the Saccharomyces cerevisiae DPP1 gene encoding for diacylglycerol pyrophosphate phosphatase. J. Biol. Chem. 273, 3278–3284

80. Fei, W., Shui, G., Gaeta, B., Du, X., Kuerschner, L., Li, P., Brown, A. J., Wenk, M. R., Parton, R. G., and Yang, H. (2008) Fld1p, a functional homologue of human seipin, regulates the size of lipid droplets in yeast. J. Biol. Chem. 283, 1753–1790

81. Werner-Washburne, M. (2004) “Sleeping beauty”: quiescence in budding yeast. J. Biol. Chem. 279, 1464–1474

82. White, T. J., eds) pp. 3–12, Academic Press, Inc., San Diego

83. Malay, O., Meggio, F., Marchiori, F., Borin, G., and Pinna, L. A. (1986) Site specificity of casein kinase II of yeast and purification. Can. J. Biochem. Physiol. 73, 911–917

84. Toke, D. A., Bennett, W. L., Dillon, D. A., Wu, W.-L., Chen, X., Ostrander, D. B., Oshiro, I., Cremesti, A., Voelker, D. R., Fischli, A. S., and Carman, G. M. (1998) Isolation and characterization of the Saccharomyces cerevisiae DPP1 gene encoding for diacylglycerol pyrophosphate phosphatase. J. Biol. Chem. 273, 3278–3284

85. Gray, J. V., Petsko, G. A., Johnston, G. C., Dinge, A. R., and Werner-Washburne, M. (2004) “Sleeping beauty”: quiescence in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 68, 187–206

86. De Virgilio, C. (2012) The essence of yeast quiescence. FEMS Microbiol. Rev. 36, 306–339

87. Thevelein, J. M. (1994) Signal transduction in yeast. Yeast 10, 1753–1790

88. Fakas, S., Konstantinou, C., and Carman, G. M. (2011) DGK1-encoded diacylglycerol kinase activity is required for phospholipid synthesis during growth resumption from stationary phase in Saccharomyces cerevisiae. J. Biol. Chem. 286, 14744–14744

89. Fei, W., Shui, G., Gaeta, B., Du, X., Kuerschner, L., Li, P., Brown, A. J., Wenk, M. R., Parton, R. G., and Yang, H. (2008) Fld1p, a functional homologue of human seipin, regulates the size of lipid droplets in yeast. J. Biol. Chem. 283, 473–482

90. Pinna, L. A. (2002) Protein kinase CK2: a challenge to canons. J. Cell Sci. 115, 3873–3878

91. Meggio, F., and Pinna, L. A. (2003) One-thousand-and-one substrates of protein kinase CK2? FEBS J. 17, 349–368
102. White, M. J., Hirsch, J. P., and Henry, S. A. (1991) The OPI1 gene of Saccharomyces cerevisiae, a negative regulator of phospholipid biosynthesis, encodes a protein containing polyglutamine tracts and a leucine zipper. J. Biol. Chem. 266, 863–872

103. Carman, G. M., and Henry, S. A. (2007) Phosphatidic acid plays a central role in the transcriptional regulation of glycerophospholipid synthesis in Saccharomyces cerevisiae. J. Biol. Chem. 282, 37293–37297

104. Loewen, C. J. R., Gaspar, M. L., Jesch, S. A., Delon, C., Ktistakis, N. T., Henry, S. A., and Levine, T. P. (2004) Phospholipid metabolism regulated by a transcription factor sensing phosphatidic acid. Science 304, 1644–1647

105. Kastaniotis, A. J., Autio, K. J., Sormunen, R. T., and Hiltunen, J. K. (2004) Htd2p/Yhr067p is a yeast 3-hydroxyacyl-ACP dehydratase essential for mitochondrial function and morphology. Mol. Microbiol. 53, 1407–1421

106. Han, G.-S., O’Hara, L., Carman, G. M., and Siniossoglou, S. (2008) An unconventional diacylglycerol kinase that regulates phospholipid synthesis and nuclear membrane growth. J. Biol. Chem. 283, 20433–20442

107. Thomas, B., and Rothstein, R. (1989) Elevated recombination rates in transcriptionally active DNA. Cell 56, 619–630

108. Sikorski, R. S., and Hieter, P. (1989) A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122, 19–27